Therefore, we specifically developed cross-reactive sdAbs, targeting both murine and human AXL protein, allowing us to demonstrate that even in the presence of an immunocompetent environment and AXL+ non-AML cells, we were still able to distinguish the specific tumor uptake from the background levels using SPECT/CT imaging, fostering the clinical potential of sdAb20. This evidence concerns the gene AXL and neoplasm.